Abstract: Certain embodiments of the present invention relate to regulation of the innate immune system and complement activation. In particular, but not exclusively certain embodiments relate to a complement regulator protein and pharmaceutical compositions thereof for use in the treatment of diseases associated with or mediated by the alternative complement pathway and methods of treating such diseases and other subject matter.
Abstract: The invention features immunogenic compositions containing anaplastic lymphoma kinase (ALK) polypeptides and methods of use thereof. The immunogenic compositions and methods of the invention may be used to treat a disease associated with ALK in a subject, such as cancer (e.g., a solid tumor cancer or an ALK+ cancer).
Type:
Grant
Filed:
February 28, 2023
Date of Patent:
July 29, 2025
Assignee:
Elicio Therapeutics, Inc.
Inventors:
Adrienne Li, Jackson Eby, Peter C. Demuth
Abstract: Provided in this disclosure are methods of treating a bacterial infection comprising administering a formulation comprising an antimicrobial peptide described herein when administered to a subject. Further provided herein are methods of treating a bacterial infection wherein the bacterial infection comprises a bacterium with a mutation in a gene resulting in antibiotic resistance.
Type:
Grant
Filed:
April 20, 2022
Date of Patent:
July 29, 2025
Assignee:
University of Pittsburgh—Of the Commonwealth System of Higher Education
Abstract: [Problem to be solved] To provide a compound having markedly higher antiviral activity than iHA 100, an intermediate for producing the compound, and a medical drug, or the like, containing the high-activity compound above. [Solution] The invention relates to a hemagglutinin-binding peptide, a pharmaceutically acceptable salts, or a solvate thereof, the hemagglutinin-binding peptide being: (1) a polypeptide comprising the amino acid sequence represented by SEQ ID NO: 1 or 2: Trp-Thr-MeGly-Asp-MePhe-MePhe-Ala-MeAla-His-Tyr-Thr-Val-hydPro-Ala-Cys (SEQ ID NO: 1), Trp-Thr-MeGly-Asp-MePhe-MePhe-Ala-MeAla-His-Tyr-Thr-Val-hydPro-Ala-Cys-Lys (SEQ ID NO: 2), or the like.
Abstract: Provided herein are novel cyclic peptides, their synthetic process, compositions, properties including stability and pharmacokinetic profiles, and applications for treating solid tumor cancers.
Abstract: The invention provides a method for preparing a biologically active complex, said method comprising dissolving a mixture of a polypeptide element, such as alphalactalbumin or fragments thereof, in powder form and oleic acid or a pharmaceutically acceptable salt thereof also in solid form, in an aqueous solvent comprising a mixture of at least two and preferably three salts, wherein the method is carried out at moderate temperatures. The preparation does not require extensive heating and so is simple and efficient to carry out.
Type:
Grant
Filed:
January 12, 2021
Date of Patent:
June 17, 2025
Assignee:
HAMLET PHARMA AB
Inventors:
Aftab Nadeem, Catharina Svanborg, Chin Shing Ho
Abstract: The invention relates to an isolated polypeptide encoded by Sghrt and related uses. In addition, methods of assessing a heart function, treating impaired heart function by inhibiting Sghrt, identifying a potential drug for treating impaired heart function, and dedifferentiating and/or proliferating a heart cell by inhibiting Sghrt are claimed.
Type:
Grant
Filed:
February 12, 2020
Date of Patent:
April 29, 2025
Assignee:
AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
Abstract: The present disclosure relates to solid state forms of Voclosporin and salts thereof, processes for preparation thereof and pharmaceutical compositions thereof.
Type:
Grant
Filed:
January 23, 2023
Date of Patent:
April 22, 2025
Assignee:
ASSIA CHEMICAL INDUSTRIES LTD.
Inventors:
Pavel Kolesa, Ladislav Cvak, Alexandr Jegorov, Katerina Ondruszova
Abstract: The present invention provides an agent for the treatment or prophylaxis of a neurodegenerative disease, containing an apoptosis inhibitor of macrophage (AIM), an AIM fragment having a biological activity of AIM, or a nucleic acid encoding the AIM or AIM fragment.
Abstract: A method for enhancing extracellular vesicle production is described. A peptide that induces polymer formation is incubated with a cell culture which results in enhanced EV production. The peptide penetrates the cells and subsequently polymerizes upon exposure to enzymes (e.g. phosphatase) within the cell. The cells that contain the newly formed polymers have an increased production of EVs. These EVs can be harvested using centrifugation techniques.
Type:
Grant
Filed:
July 2, 2021
Date of Patent:
April 1, 2025
Assignees:
Research Foundation of the City University of New York, Japanese Foundation for Cancer Research
Inventors:
Hiroshi Matsui, Kiyotaka Shiba, Min A. Kang
Abstract: Glucose-responsive zwitterionic polymer-insulin-saccharide compositions are provided according to aspects of the present disclosure which include a zwitterionic polymer, an insulin moiety, a saccharide moiety, and a saccharide binding molecule. Methods of use of glucose-responsive zwitterionic polymer-insulin-saccharide compositions according to aspects of the present disclosure include administration to human patients to alleviate conditions, such as diabetes, which are responsive to administration of insulin.
Abstract: Polypeptides and compositions having the polypeptides. Methods for treating cancer utilizing polypeptides and compositions having the polypeptides. The polypeptides can bind to human PD-L1 protein. The polypeptides can block the PD-1/PD-L1 interaction.
Type:
Grant
Filed:
October 21, 2021
Date of Patent:
March 25, 2025
Inventors:
Kun Cheng, Hao Liu, John Fetse, Umar-Farouk Mamani
Abstract: Disclosed herein are cyclosporine compounds and methods for use in the treatment or prevention of neutrophil-mediated inflammation, wherein the compounds inhibit the activity of MRP2 and FPR1.
Type:
Grant
Filed:
August 20, 2019
Date of Patent:
March 18, 2025
Assignee:
BACAINN BIOTHERAPEUTICS, LTD.
Inventors:
Chris Murphy, Ronald Farquhar, Roland E. Dolle
Abstract: The present application provides a biological active peptide from seawater pearl, the sequence of which is Ile-Pro-Ser-Thr-Thr-Pro-Phe-Pro-Ser-Thr-Thr-Val-Ala-Thr-Thr-Thr-Met, and the name of which is SCOL polypeptide. The biological active peptide can improve an ACE2 enzyme activity to 3.76 times, and can be applied in preparation of a drug improving an ACE2 activity, treating hypertension, anti-heart failure, anti-tissue fibrosis, anti-inflammation, and type 2 diabetes mellitus and the complication thereof, and relieving neuropathic pain. The biological active peptide can be specifically bound to the ACE2, effectively inhibits the 65% binding between novel coronavirus S protein and the ACE2, can be applied in preparation of an anti-coronavirus infection drug as an inhibitor, and specifically applied in preparation of anti-novel coronavirus drug.
Type:
Grant
Filed:
January 18, 2024
Date of Patent:
March 11, 2025
Assignees:
ZHEJIANG QINGRONG BIOTECHNOLOGY DEVELOPMENT CO., LTD, YANGTZE DELTA REGION INSTITUTE OF TSINGHUA UNIVERSITY, ZHEJIANG
Abstract: Provided herein are compositions and methods for treating and/or preventing pathogenic fungal infection and for maintenance of microbiome commensalism. In particular, provided herein are compositions comprising modified peptide YY (PYY) peptides and therapeutic and/or prophylactic methods of use thereof.
Type:
Grant
Filed:
May 16, 2018
Date of Patent:
March 4, 2025
Assignee:
The University of Chicago
Inventors:
Eugene B. Chang, Joseph F. Pierre, Katharine A. Harris
Abstract: The subject invention provides therapeutic compositions, and uses thereof for the treatment or amelioration of injury to small intestine mucosa. In preferred embodiments, the composition comprises one or more nutrients and/or electrolytes that acquire or retain considerable absorptive capacity.
Type:
Grant
Filed:
August 1, 2023
Date of Patent:
March 4, 2025
Assignee:
University of Florida Research Foundation, Incorporated
Inventors:
Sadasivan Vidyasagar, Paul Okunieff, Lurong Zhang
Abstract: SorCS2 related lipidated cyclic peptides, cyclic peptides, lipidated linear peptides, linear peptides which may be of use in medicine, and related aspects.
Type:
Grant
Filed:
May 10, 2024
Date of Patent:
March 4, 2025
Assignee:
Teitur Trophics ApS
Inventors:
Anders Dalby, Simon Mølgaard Jensen, Mathias Kaas Ollendorff, Kristian Strømgaard, Keld Fosgerau
Abstract: The invention provides compositions and kits including at least one nucleic acid or polypeptide molecule encoding for a mutant CoChop protein. Methods of the invention include administering a composition comprising a mutant CoChop to a subject to preserve, improve, or restore phototransduction. Preferably, the compositions and methods of the invention are provided to a subject having impaired vision, thereby restoring vision to normal levels.
Type:
Grant
Filed:
May 19, 2021
Date of Patent:
February 25, 2025
Assignee:
Wayne State University
Inventors:
Zhuo-Hua Pan, Tushar Ganjawala, Qi Lu, Gary Abrams
Abstract: Compositions and methods for improving bruising, stimulating elastin and/or collagen production, stimulating intrinsic hyaluronic acid production, stimulating adipogenesis, reducing inflammation, or combinations thereof are provided herein. Compositions and methods described herein may be used following a cosmetic procedure.